AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03554447
Drug: Escitalopram 20 mg tablet plus Pentoxifylline 400Mg Tablet
RxNorm normalized name: escitalopram 20 MG
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Selective serotonin reuptake inhibitor plus phosphodiesterase inhibitor with anti-inflammatory properties
Trial: NCT03554447
Drug: Escitalopram 20 mg tablet + Placebo
RxNorm normalized name: escitalopram 20 MG
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Selective serotonin reuptake inhibitor plus placebo
Trial: NCT01510522
Drug: Glucophage
RxNorm normalized name: Glucophage
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Glucophage Powder for oral solution in sachets (metformin hydrochloride in 850mg strengths) Dosing schedule: \> 1.700mg/day for 6 month
Trial: NCT01510522
Drug: Glucophage
RxNorm normalized name: Glucophage
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Glucophage tablets (metformin hydrochloride in 850mg strengths)~Dosing schedule: \> 1.700mg/day for 6 month
Trial: NCT01326533
Drug: hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thirteen weeks of oral hydroxychloroquine (400 mg/day) provided as capsules
Trial: NCT00326469
Drug: lanreotide (Autogel formulation)
DrugBank: Lanreotide (DB06791)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 120mg administered via deep subcutaneous injection every 28 days for up to 24 months or until disease progression.
Trial: NCT00429169
Drug: Paroxetine
RxNorm normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosage will be 25 mg every day for 2 weeks, then 37.5 mg every day for 2 weeks, and then optional increase to 50 mg every day for the remainder of treatment.
Trial: NCT00429169
Drug: Bupropion
RxNorm normalized name: Bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosage will be 150 mg every day for 2 weeks, then 300 mg every day for 2 weeks, and then optional increase to 450 mg every day for the remainder of treatment.
Trial: NCT03878784
Drug: Imigran
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients will undergo this intervention on one of two study days
Trial: NCT00767273
Drug: FLT
RxNorm normalized name: FLT201
DrugBank: FLT201 (DB18419)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00767273
Drug: FDG
RxNorm normalized name: 18F-FDG
DrugBank: Fludeoxyglucose (18F) (DB09502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00297570
Drug: Pegylated Interferon and Imatinib
RxNorm normalized name: Pegylated interferon alpha-2a
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02400021
Drug: Prometrium
RxNorm normalized name: Prometrium
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03596424
Drug: Ketamine Hydrochloride
RxNorm normalized name: Ketamine Hydrochloride
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraoperative bolus and infusion (see arm description)
Trial: NCT03596424
Drug: Dexmedetomidine Hydrochloride
RxNorm normalized name: Dexmedetomidine Hydrochloride
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intraoperative bolus and infusion (see arm description)
Trial: NCT00778908
Drug: Concomitant cisplatin chemotherapy
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cisplatin:40mg/m2 weekly infusion for 6 weeks
Trial: NCT03364309
Drug: Ixekizumab
RxNorm normalized name: Ixekizumab
DrugBank: Ixekizumab (DB11569)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered SC
Trial: NCT03708822
Drug: Docetaxel and Cisplatin and Nimotuzumab
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous nimotuzumab (200 mg on days 1, 8, and 15) ; Intravenous docetaxel (75 mg/m2 on day 1) ; Intravenous cisplatin (75 mg/m2 on day 1) ;
Trial: NCT01750723
Drug: Acetazolamide
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 g diluted in 10 ml saline, i.v. bolus injection.
Trial: NCT02519595
Drug: Ketamine IV 1mg/kg
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intervention: Ketamine IV 1mg/kg
Trial: NCT02519595
Drug: Ketamine IV 1.5mg/kg
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intervention: Ketamine IV 1.5 mg/kg
Trial: NCT02519595
Drug: Ketamine IV 2mg/kg
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intervention: Ketamine IV 2 mg/kg
Trial: NCT02464722
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 mcg/kg iv loading dose of remifentanil over a period of 60 seconds. Later, an infusion was started at the rate of 0.2-0.4mcg/kg/min.
Trial: NCT02464722
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anesthesia was induced with propofol 2 mg kg-1
Trial: NCT02464722
Drug: Rocuronium
RxNorm normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anesthesia was induced with rocuronium 0.6 mg kg-1
Trial: NCT00258323
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20mg/m2d/IV continuous infusion x days
Trial: NCT00258323
Drug: Iressa
RxNorm normalized name: Iressa
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 250mg po qd days 1-28 then x 2 years
Trial: NCT03676140
Drug: Albendazole on Day 1
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albendazole 400 mg oral tablet Single Dose Treatment on D1
Trial: NCT01789203
Drug: Ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be randomized 2:1 active comparator, Cipro, to placebo comparator.
Trial: NCT03676140
Drug: Ivermectin on Day 1
RxNorm normalized name: ivermectin Topical Solution [Iver-On]
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivermectin 200 µg/kg oral tablet Single Dose Treatment on Day 1
Trial: NCT03676140
Drug: Diethylcarbamazine on day 1
DrugBank: Diethylcarbamazine (DB00711)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diethylcarbamazine 6 mg/kg oral tablet Single Dose Treatment on Day 1
Trial: NCT00615992
Drug: Tiotropium
RxNorm normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04193592
Drug: Pirfenidone
RxNorm normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pirfenidone will be titrated over 14 days, as tolerated, to the full dose of 2403 mg per day, as follows: Days 1 - 7: one capsule TID; Days 8 - 14: two capsules TID; Days 15 to week 52: three capsules TID. Dose may be reduced to manage an adverse event.
Trial: NCT03959371
Drug: Ruxolitinib
RxNorm normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Observational study including patients with myelofibrosis being treated with ruxolitinib in a real world setting. Patients are treated according to current indications.
Trial: NCT02711982
Drug: methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: within 5 days from trauma
Trial: NCT02028884
Drug: Satralizumab
RxNorm normalized name: SATRALIZUMAB
DrugBank: Satralizumab (DB15762)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Satralizumab will be administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).
Trial: NCT01291407
Drug: S-1
RxNorm normalized name: LIS-1
DrugBank: Tegafur (DB09256)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: S-1,30mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.
Trial: NCT01291407
Drug: S-1
RxNorm normalized name: LIS-1
DrugBank: Tegafur (DB09256)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: S-1,40mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.
Trial: NCT01291407
Drug: S-1
RxNorm normalized name: LIS-1
DrugBank: Tegafur (DB09256)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: S-1,50mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner
Trial: NCT01291407
Drug: S-1
RxNorm normalized name: LIS-1
DrugBank: Tegafur (DB09256)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: S-1,60mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.
Trial: NCT01291407
Drug: S-1
RxNorm normalized name: LIS-1
DrugBank: Tegafur (DB09256)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: S-1,70mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.
Trial: NCT01291407
Drug: S-1
RxNorm normalized name: LIS-1
DrugBank: Tegafur (DB09256)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: S-1,80mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.
Trial: NCT03478033
Drug: Rifampicin
RxNorm normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifampicin capsules, 150mg
Trial: NCT03478033
Drug: Rifabutin
RxNorm normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifabutin capsules, 150mg
Trial: NCT01797913
Drug: gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: gemcitabine，1000mg/m2，ivgtt，DAY1\&DAY8
Trial: NCT04188145
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Option 1 and Option 2 : D1 bevacizumab 7.5 mg/kg IV (D1=D21). See smPCs for infusion time of bevacizumab.~Or Option 3: D1 bevacizumab 5 mg/kg IV (D1=D15). See smPCs for infusion time of bevacizumab
Trial: NCT02491606
Drug: Tafenoquine
RxNorm normalized name: tafenoquine
DrugBank: Tafenoquine (DB06608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tafenoquine 200mg and 400 mg
Trial: NCT00298454
Drug: Furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01969890
Drug: G-CSF administration
RxNorm normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Zarzio - 5 microg/kg bis in die for 6 days
Trial: NCT02024308
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/m2, IV (in the vein) in combination with cytarabine 1.4mg/m2/d for 5 days with each cycle of 28 days. Number of cycles: 4
Trial: NCT02024308
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2000mg/m2/12h, IV (in the vein) for 3 days with each cycle of 28 days. Number of cycles: 4
Trial: NCT00125151
Drug: C1 inhibitor concentrate (C1-esteraseremmer-N)
RxNorm normalized name: C1 INHIBITOR
DrugBank: Human C1-esterase inhibitor (DB06404)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00273455
Drug: bimatoprost 0.03%
RxNorm normalized name: BIMATOPROST 0.03% SOLN,OPH
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00273455
Drug: dorzolamide 2%/timolol maleate 0.5% fixed combination
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04209933
Drug: Bismuth potassium citrate containing quadruple therapy
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
DrugBank: Potassium citrate (DB09125)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bismuth potassium citrate:given for 14 days at a dose of bismuth potassium citrate 220 mg 0 BID,rabeprazole 10 mg BID, amoxicillin 1000 mg BID, and clarithromycin 500 mg BID
Trial: NCT04209933
Drug: Colloidal pectin bismuth capsules containing quadruple therapy
RxNorm normalized name: bismuth / pectin
DrugBank: Pectin (DB11158)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth potassium citrate:given for 14 days at a dose of Colloidal pectin bismuth capsules 200 mg 0 BID,rabeprazole 10 mg BID, amoxicillin 1000 mg BID, and clarithromycin 500 mg BID
Trial: NCT04138628
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The study drug will be given according to current recommendations as systemic treatment every third week for 12 months or until progression. Treatment will be initiated within 28 days of detection of ctDNA.
Trial: NCT01151254
Drug: Isoflurane/sevoflurane
DrugBank: Isoflurane (DB00753)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Volatile for sedation in the CVICU while intubated
Trial: NCT00398502
Drug: MOA-728
RxNorm normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02004613
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine
Trial: NCT02327078
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: specified dose and dosing schedule
Trial: NCT02327078
Drug: Epacadostat
RxNorm normalized name: epacadostat
DrugBank: Epacadostat (DB11717)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral twice daily continuous at the protocol-defined dose
Trial: NCT00354094
Drug: [S,S]-Reboxetine
DrugBank: Reboxetine (DB00234)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01561781
Drug: Digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tablets 0.25mg, single dose
Trial: NCT01561781
Drug: Vandetanib
RxNorm normalized name: Vandetanib
DrugBank: Vandetanib (DB05294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tablets, 300 mg, single dose
Trial: NCT02664220
Drug: Povidone-iodine irrigation
RxNorm normalized name: povidone-iodine Irrigation Product
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Povidone-iodine (PVI) is an antiseptic solution consisting of polyvinylpyrrolidone with water, iodide, and 1% available iodine. It has bactericidal ability against a large array of pathogens, including those pathogens which commonly cause postoperative IAA in children with perforated appendicitis.~1% PVI will be used. Once the appendix has been removed and hemostasis ensured, the surgeon will perform the irrigation with 10cc/kg (minimum 100ml and maximum 1000ml) of 1% PVI. After completing the irrigation, the surgeon will suction out all intra-abdominal fluid into a suction canister.
Trial: NCT04209933
Drug: Colloidal pectin bismuth particles A quadruple therapy
RxNorm normalized name: bismuth / pectin
DrugBank: Pectin (DB11158)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth potassium citrate:given for 14 days at a dose of Colloidal pectin bismuth particles 150 mg BID,rabeprazole 10 mg BID, amoxicillin 1000 mg BID, and clarithromycin 500 mg BID
Trial: NCT04209933
Drug: Colloidal pectin bismuth particles B quadruple therapy
RxNorm normalized name: bismuth / pectin
DrugBank: Pectin (DB11158)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth potassium citrate:given for 14 days at a dose of Colloidal pectin bismuth particles 300 mg BID,rabeprazole 10 mg BID, amoxicillin 1000 mg BID, and clarithromycin 500 mg BID
Trial: NCT00984282
Drug: Sorafenib (Nexavar, BAY43-9006)
RxNorm normalized name: sorafenib 200 MG [Nexavar]
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorafenib 400 mg will be administered orally, twice daily (approximately every 12 hours).
Trial: NCT00101725
Drug: crofelemer
RxNorm normalized name: Crofelemer
DrugBank: Crofelemer (DB04941)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00869518
Drug: rifabutin plus trimethoprim sulfamethoxazole
RxNorm normalized name: sulfamethoxazole / trimethoprim
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rifabutin 300 mg PO daily or equivalent depending on concomitant medications plus trimethoprim-sulfamethoxazole 1 DS tab twice daily both for 7 days
Trial: NCT00869518
Drug: placebo plus trimethoprim-sulfamethoxazole
RxNorm normalized name: sulfamethoxazole / trimethoprim
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: placebo plus trimethoprim-sulfamethoxazole 1 DS tab twice daily both for 7 days
Trial: NCT00414128
Drug: mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2-3g/day for 3-6 months, in tablet, capsule or liquid form
Trial: NCT03154294
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel will be diluted prior to infusion in 0.9% Sodium Chloride for Injection, USP; 5% Dextrose Injection, USP; 5% Dextrose and 0.9% Sodium Chloride Injection, USP; or 5% Dextrose in Ringer's Injection to a final concentration of 0.3 to 1.2mg/mL. At ambient temperature (approximately 25°C) and room lighting conditions the solution is physically and chemically stable for up to 27 hours. The diluted product will be prepared and stored in glass, polypropylene, or polyolefin containers; DEHP-containing (polyvinyl chloride (PCV)) containers should not be used. Paclitaxel will be administered using a vented Paclitaxel set with in-line 0.22-micron filter and run over 1 hour.
Trial: NCT04329832
Drug: Hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in the hydroxychloroquine arm will receive hydroxychloroquine 400 mg by mouth twice daily for 1 day, then 200 mg by mouth twice daily for 4 days (dose reductions for weight \< 45 kg or GFR (glomerular filtration rate)\<50ml/min). For patients \< 45kg, doses will be halved. For patients with GFR\<50ml/min, the final dose of hydroxychloroquine will not be administered. If the patient has already received hydroxychloroquine prior to randomization (no more than 2 days), the prior doses will count toward the 5-day total.
Trial: NCT04508023
Drug: Rivaroxaban
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive rivaroxaban 10 mg tablet orally once daily.
Trial: NCT00990106
Drug: prazosin hydrochloride
RxNorm normalized name: Prazosin Hydrochloride
DrugBank: Prazosin (DB00457)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subject will be titrated up to the optimum tolerated dose based on the Dosing Algorithm. Males and females will be titrated differently with females titrated slower and to a lower maximum daily dose. The first dose will be taken while the participant is in bed for the night to avoid orthostatic syncope, an uncommon but recognized first dose effect of prazosin or any alpha-1 antagonist if started at a high dose. The first dose effect is avoidable by starting treatment with a low dose (1 mg at bedtime) then titrating the dose upward gradually.
Trial: NCT00556920
Drug: COREG CR
RxNorm normalized name: Coreg CR
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04256434
Drug: Dinalbuphine sebacate
RxNorm normalized name: Dinalbuphine sebacate
DrugBank: Dinalbuphine sebacate (DB15341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg Dinalbuphine sebacate
Trial: NCT04256434
Drug: Nalbuphine HCl
RxNorm normalized name: nalbuphine HCl
DrugBank: Nalbuphine (DB00844)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg Nalbuphine
Trial: NCT01198353
Drug: Ziprasidone
RxNorm normalized name: Ziprasidone
DrugBank: Ziprasidone (DB00246)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100% of the past antipsychotic dose will be maintained in week 1, using flexible dosing of 0-100% during next 3 weeks and then discontinued. Ziprasidone will be maintained with flexible dosing of 40-160mg/day during the study period.
Trial: NCT03154294
Drug: TAK-228
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-228 will be provided in 30-ct, 60-cc high density polyethylene (HDPE) bottles with polypropylene, child-resistant caps and induction seal. TAK-228 will be administered on an empty stomach. It is recommended that each dose of TAK-228 + TAK-117 be given PO with 8 ounces (240 mL) of water. Patients should be instructed to refrain from eating and drinking (except for water and prescribed medications) for 2 hours before and 1 hour after each dose.
Trial: NCT03154294
Drug: TAK-117
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-117 will be provided in 30-ct, 60-cc high density polyethylene (HDPE) bottles with polypropylene, child-resistant caps and induction seal. TAK-117 will be administered on an empty stomach. It is recommended that each dose of TAK-228 + TAK-117 be given PO with 8 ounces (240 mL) of water. Patients should be instructed to refrain from eating and drinking (except for water and prescribed medications) for 2 hours before and 1 hour after each dose.
Trial: NCT03105661
Drug: Labetalol Hydrochloride 200 mg
RxNorm normalized name: labetalol hydrochloride 200 MG
DrugBank: Labetalol (DB00598)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anti-hypertensive prescribed for increased cardiac output as determined by Impedance Cardiography
Trial: NCT03105661
Drug: NIFEdipine 60 mg
RxNorm normalized name: nifedipine 60 MG
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anti-hypertensive medication prescribed for increased systemic vascular resistance as determined by Impedance Cardiography
Trial: NCT03105661
Drug: Atenolol 25 mg
RxNorm normalized name: atenolol 25 MG
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anti-hypertensive prescribed for increased cardiac output with tachycardia or maternal pulse rate 110 or greater